New Year, new on BTKi: PERSEUS Study misses the primary endpoint
First of all, I would like to wish all readers of MS-DocBlog a happy and
Continue reading
New Year, new on BTKi: PERSEUS Study misses the primary endpoint
First of all, I would like to wish all readers of MS-DocBlog a happy and successful new year. – Stay healthy and hopeful, despite all adversities. Speaking of adversities – this brings us right back
Continue reading
Merry Christmas and a Happy New Year 2026
The year 2025 was not an easy year. It was characterized by intense political, economic and social developments. The war in Ukraine, the Gaza crisis, geopolitical tensions, but also domestic political disputes kept us on
Continue reading
BTKi – the direction is right.
On November 10, 2025, Roche released a press release announcing that Fenebrutinib has reached its primary endpoint in the first Phase III trial (FENhance 2) of two similarly designed pivotal Phase III trials (FENhance 1
Continue reading
Gender Gap in the Use of Immunomodulatory Therapies
Women of childbearing age are, compared to men, underrepresented in MS therapy. This was shown by a recent study. There is a gender gap in the use of immunomodulatory therapies (DMT). However, this does not
Continue reading
News from ECTRIMS 2025 (2)
As already stated in the previous article “News from ECTRIMS (1)“: We have now become very good at controlling focal inflammation in MS – that is, the inflammatory response triggered by the influx of peripheral
Continue reading
News from ECTRIMS 2025 (1)
Those who have been with DocBlog for a while know: autumn is congress time. As always at this time, the world’s largest MS meeting took place again this year – almost 10,000 MS experts from
Continue reading
Development of MS Therapies
There has been a lot of progress in the development of MS therapy, since the first interferon for multiple sclerosis came on the market in the mid-90s. There are now almost 20 immunomodulatory agents approved.
Continue reading
Progressive Forms, Farewell?
So far, multiple sclerosis has been divided into 5 subtypes. Researchers are increasingly moving away from this model. Instead, MS appears to be a single entity, a dynamic process. Does this mean we can now
Continue reading
MS Patients as Organ Donors?
This blog post is dedicated to the question of whether people with MS can serve as organ donors, which types of organ donations are permissible, and under what conditions. MS-afflicted father wants to donate kidney
Continue reading
Multiple Sclerosis and Other Chronic Inflammatory Diseases
In the current issue of the German Medical Journal, there is a nice summary of drug therapy in the simultaneous occurrence of Multiple Sclerosis (MS) and other chronic inflammatory diseases such as psoriasis, rheumatoid arthritis
Continue reading
